EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudie

Stage-specific efficacy of osimertinib in treatment-naïve EGFR-mutant non-small cell lung cancer according to baseline genetic alterations in circulating tumor DNA

Yoshihiko Taniguchi iD, Akihiro Tamiya, Mitsuo Osuga, Shun-Ichi Isa, Keiichi Nakamura, Yasuyuki Mizumori, Tsutomu Shinohara, Hidetoshi Yanai, Katsumi Nakatomi, Masahide Oki, Masahide Mori, Tomohito Kuwako und 4 weitere

Investigational New Drugs · 2025

DOI: 10.1007/s10637-024-01500-9 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Investigational New Drugs, 2025. Verfasst von Yoshihiko Taniguchi und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, NHO Kinki Chuo Chest Medical Center, 1180 Nagasone-cho, Kita-ku, Sakai City, Osaka, 591-8555, Japan. taniguchi.yoshi…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Aniline Compounds, Acrylamides. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 43 Literaturangaben. Gefördert von: AstraZeneca.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The impact of clinical stage on the effectiveness of osimertinib for epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC) remains unexamined. We investigated osimertinib therapeutic efficacy variation between stage IVA or lower and stage IVB EGFR mutation-positive lung cancers, focusing on differences in pretreatment co-occurring genetic alterations in circulating tumor DNA. This was a secondary analysis of the ELUCIDATOR study, a multicenter prospective observational study in Japan that assessed the mechanisms underlying resistance to osimertinib as a first-line treatment for advanced NSCLC with EGFR mutations. We compared the progression-free survival (PFS), overall survival (OS), and pretreatment co-occurring genetic alterations detected in plasma between patients with stages IVA (n = 83) and IVB disease (n = 84). Multivariate analysis of PFS and OS revealed that stage IVB was associated with a poor prognosis (hazard ratio [HR]: 2.03, 95% confidence interval [CI]: 1.36-3.04, p < 0.001, HR: 2.35, 95% CI: 1.45-3.90, p < 0.001, respectively). Pre-osimertinib treatment, significantly more TP53- (52.4% vs. 27.7%, p = 0.002), EGFR amplification- (58.3% vs. 23.2%, p < 0.001), and MET amplification-positive cases (22.6% vs. 7.2%, p = 0.008) were found among stage IVB than among stage IVA or lower cases. Patients with EGFR-positive NSCLC in stage IVB exhibited significantly shorter PFS and OS than those in earlier stages when treated with first-line osimertinib. The prevalence of baseline TP53 mutations, EGFR amplification, and MET amplification in plasma were significantly higher in stage IVB cases, implicating them in the worse outcomes of this group.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsAniline CompoundsAcrylamidesCirculating Tumor DNAAntineoplastic AgentsProtein Kinase InhibitorsHumansErbB ReceptorsFemaleMaleMiddle AgedAgedMutationNeoplasm StagingProspective StudiesAdultAged, 80 and overIndolesPyrimidines

Stichwörter der Autor:innen

Circulating tumor DNAEpidermal growth factor receptor mutationNon-small cell lung cancerOsimertinibSurvival

Substanzen

osimertinibErbB ReceptorsAniline CompoundsAcrylamidesEGFR protein, humanCirculating Tumor DNAAntineoplastic AgentsProtein Kinase InhibitorsIndolesPyrimidines

Autor:innen und Institutionen

  • Department of Internal Medicine, NHO Kinki Chuo Chest Medical Center, 1180 Nagasone-cho, Kita-ku, Sakai City, Osaka, 591-8555, Japan. taniguchi.yoshihiko.ny@mail.hosp.go.jp.
  • Department of Internal Medicine, NHO Kinki Chuo Chest Medical Center, 1180 Nagasone-cho, Kita-ku, Sakai City, Osaka, 591-8555, Japan.
  • Center for Biomedical Sciences, Wakayama Medical University, Wakayama, Japan.
  • Clinical Research Center, NHO Kinki Chuo Chest Medical Center, Sakai, Osaka, Japan.
  • Department of Respiratory Medicine, NHO Asahikawa Medical Center, Asahikawa, Hokkaido, Japan.
  • Department of Respiratory Medicine, NHO Himeji Medical Center, Himeji, Hyogo, Japan.

ORCID-Profile: Yoshihiko Taniguchi

Förderung

  • AstraZeneca

Zitieren

APA

Taniguchi, Y., Tamiya, A., Osuga, M., Isa, S. I., Nakamura, K., Mizumori, Y., Shinohara, T., Yanai, H., Nakatomi, K., Oki, M., Mori, M., Kuwako, T., Yamazaki, K., Shimada, M., Ando, M., & Koh, Y. (2025). Stage-specific efficacy of osimertinib in treatment-naïve EGFR-mutant non-small cell lung cancer according to baseline genetic alterations in circulating tumor DNA. Investigational New Drugs. https://doi.org/10.1007/s10637-024-01500-9

Vancouver

Taniguchi Y, Tamiya A, Osuga M, Isa SI, Nakamura K, Mizumori Y, et al. Stage-specific efficacy of osimertinib in treatment-naïve EGFR-mutant non-small cell lung cancer according to baseline genetic alterations in circulating tumor DNA. Investigational New Drugs. 2025. doi:10.1007/s10637-024-01500-9

BibTeX
@article{Taniguchi2025,
  author = {Taniguchi, Yoshihiko and Tamiya, Akihiro and Osuga, Mitsuo and Isa, Shun-Ichi and Nakamura, Keiichi and Mizumori, Yasuyuki and Shinohara, Tsutomu and Yanai, Hidetoshi and Nakatomi, Katsumi and Oki, Masahide and Mori, Masahide and Kuwako, Tomohito and Yamazaki, Koji and Shimada, Masahiro and Ando, Masahiko and Koh, Yasuhiro},
  title = {Stage-specific efficacy of osimertinib in treatment-naïve EGFR-mutant non-small cell lung cancer according to baseline genetic alterations in circulating tumor DNA},
  journal = {Investigational New Drugs},
  year = {2025},
  doi = {10.1007/s10637-024-01500-9}
}
Kostenlos starten →